Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
about
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesA systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Serum concentrations of Erlotinib at a dose of 25 mg daily.Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide arrayRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.A growing family: adding mutated Erbb4 as a novel cancer targetDifferential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerEfficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.Mechanisms of resistance to EGFR targeted therapies.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Gefitinib for the treatment of non-small-cell lung cancer.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates.Resisting Resistance: Targeted Therapies in Lung Cancer.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.Gefitinib for the treatment of non-small-cell lung cancer.Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.Hotspot oncomutations: implications for personalized cancer treatment.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Acquired resistance to TKIs in solid tumours: learning from lung cancer.Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancerManagement of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
P2860
Q27014117-EDC8A5C0-26FB-494F-9942-0B1301161DD1Q27852979-F9CADEC6-7847-42C3-86BF-2A588A5AAB17Q28075511-2F744081-10CC-4FD6-80CF-45A4E44E1C62Q33599057-626DBB04-8152-4209-9978-E2FA71D3A9CBQ34002791-A768B8D1-8B69-4E16-A8A8-268BA5784131Q34031229-FC8F13EB-7958-473F-B106-13ADA4462478Q34097177-9D25C44C-227A-45B1-8CEA-D2990DEE8747Q34158755-D35A2AB6-BB8C-4E09-8A23-8FA9FEE4706DQ34773458-13EED967-67E1-4497-807F-90A95B4AB83CQ35667787-2FFF80AC-6A7E-4442-9027-943B0EE58EA6Q35896406-45F328E5-74D5-4801-81CA-17F70F5F6D32Q36062442-6AFF9E97-2394-4F7B-8DD0-1969C4F8094AQ36112781-CAEF6376-CC6E-4CE7-B8A2-2D2482C91C5EQ36260477-0BDF7EB2-DAD3-4AF3-9AD0-541726344254Q36351290-A9475F05-D333-4567-98C0-9BAC3FBB4A04Q36887721-51868325-0D2D-4C08-B728-CE34882C8E03Q37000538-B16578B5-A47C-4098-A621-0FD723E87C55Q37321925-9B661E49-22CB-4265-BA45-BCADEC6332A1Q37334996-F822D9F4-4AF2-4D51-B049-4753B1C876AFQ37357287-3230AD80-BABA-4A26-A49C-D70491B94173Q37379113-98D44914-D808-44CB-A80D-577D922A5869Q37379240-B08747FB-0703-4124-B50B-D97F92D23A0EQ37388238-BCDE377D-E43D-4609-900B-EDFA90632E4CQ37634419-D369B1A3-9CE5-4E99-8269-9CD2E4FAADCEQ37708836-5C787EC1-74B9-444D-B48A-12B7EF27C115Q37738913-B7164563-1A67-4F9E-890F-C0D35105D2E4Q37755154-C091B560-A7F6-46E0-ACCE-83BCC1399A8CQ37838120-CA17ED60-F59E-47C3-A934-D99CA19A512BQ37894095-C7684065-AAAE-4DB7-A17C-7A652723C6F5Q38030603-68306020-A6E0-440C-8681-822D2850FBDEQ38213830-70F38BF5-23C8-4D9E-99E5-E4D38047171FQ38224967-AC740463-656C-4F4E-B348-ED16AB4CCBDBQ38390044-405074BC-D3E7-48F2-A6CB-77C5C33937E7Q38390205-E718EAE2-0775-4969-9B08-53F074941F79Q38525856-50ABD99E-80B6-488C-8079-CC70A52CCB40Q38673369-15569A8E-C6FA-480E-B532-A777F57D4988Q38685481-F1C9EB87-7725-4014-88A5-4DBFE544D079Q38869420-904B92E1-7B83-44F6-A95B-73896324C08AQ38976895-C059DD61-7170-499F-877F-B1EE6BF679EAQ39106800-77F34DF3-19E4-4709-BB94-5567112299E6
P2860
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Differential responses to erlo ...... or T790M secondary mutations.
@en
Differential responses to erlotinib in epidermal growth factor receptor
@nl
type
label
Differential responses to erlo ...... or T790M secondary mutations.
@en
Differential responses to erlotinib in epidermal growth factor receptor
@nl
prefLabel
Differential responses to erlo ...... or T790M secondary mutations.
@en
Differential responses to erlotinib in epidermal growth factor receptor
@nl
P356
P1476
Differential responses to erlo ...... S or T790M secondary mutations
@en
P2093
Susan T Schumer
Susumu Kobayashi
P304
1182-4; author reply 1184-6
P356
10.1200/JCO.2007.14.9039
P407
P577
2008-03-01T00:00:00Z